Acetylcholinesterase inhibitors in the context of therapeutic strategies to combat Alzheimer’s disease

Bibliography

• ALZHEIMER A: Ueber eine eigenartige Erkrankung der Hirnrinde. AlIgemeine Z Psychiatric. Psychisch-Gerichtlichen Medizin (1907) 64:146–148.
   Google Scholar
• SELKOE DJ: Alzheimer's disease: genes, proteins, and therapy. Physic] Rev (2001) 81:741–766.
   Google Scholar
• SELKOE DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (1999) 399:A23–31.
   PubMed Web of Science ®Google Scholar
• ••This seminal review paper represents anattempt to consistently organise evidence on the AD neurotoxic cascade. Interpretation of the biological phenomena is carried out at a cellular level, such that the individuation of putative molecular targets for pharmacological intervention is facilitated.
   Google Scholar
• HARDY J, SELKOE DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 297:353–356.
   PubMed Web of Science ®Google Scholar
• BARTUS RT, DEAN RL 3, BEER B, LIPPA AS: The cholinergic hypothesis of geriatric memory dysfunction. Science (1982) 217:408–414.
   PubMed Web of Science ®Google Scholar
• BARTUS RI: On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol (2000) 163:495–529.
   PubMed Web of Science ®Google Scholar
• SUMMERS WK, MAJOVSKI LV, MARSH GM, TACHIKI K, KLING A: Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N. Engl. J. Med. (1986) 315:1241–1245.
   PubMed Web of Science ®Google Scholar
• GIACOBINI E, BECKER R, MCILHANY M, KUMAR V: Intracerebroventricular administration of cholinergic drugs: preclinical trials and clinical experience in Alzheimer patients. In: Current research in Alzheimer therapy Giacobini E, Becker R (Eds), Taylor & Francis (1988):113–122.
   Google Scholar
• MCGLEENON BM, DYNAN KB, PASSMORE AP: Acetylcholinesterase inhibitors in Alzheimer's disease. Br. J. Clin. Pharmacol (1999) 48:471–480.
   PubMed Web of Science ®Google Scholar
• GAUTHIER S: Acetylcholinesterase inhibitors in the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs (1999) 8:1511–1520.
   PubMedGoogle Scholar
• GIACOBINI E: Cholinesterase inhibitors: from the Calabar bean to Alzheimer's disease. In: Cholinesterases and cholinesterase inhibitors. Giacobini E (Ed.), Martin Dunitz Ltd (2000):181–226.
   Google Scholar
• ••This chapter provides an extendeddescription of the AChEIs used for the treatment of AD, mainly from pharmacological and clinical points of view. The whole book, edited by Giacobini, is an indispensable reference text for those working in the field of cholinesterase inhibitors.
   Google Scholar
• MOGHUL S, WILKINSON D: Use of acetylcholinesterase inhibitors in Alzheimer's disease. Expert Rev Neurotherapeutics (2001) 1:61–69.
   PubMedGoogle Scholar
• BENZI G, MORETTI A: Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? Eur.J. Pharmacol (1998) 346:1–13.
   Google Scholar
• FROLICH L: The cholinergic pathology inAlzheimer's disease - discrepancies between clinical experience and pathophysiological findings. j. Neural. Transm. (2002) 109:1003–1013.
   PubMedGoogle Scholar
• •A critical reappraisal of the cholinergic hypothesis at the light of recent clinical and pathophysiological data.
   Google Scholar
• DAVIS KL, MOHS RC, MARIN D et al.: Cholinergic markers in elderly patients with early signs of Alzheimer disease. Jama (1999) 281:1401–1406.
   PubMed Web of Science ®Google Scholar
• DEKOSKY ST, IKONOMOVIC MD, STYREN SD et al.: Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Nemo]. (2002) 51:145–155.
   PubMed Web of Science ®Google Scholar
• SOREQ H, SEIDMAN S: Acetylcholinesterase-new roles for an old actor. Nat. Rev Neurosci. (2001) 2:294–302.
   PubMed Web of Science ®Google Scholar
• GRISARU D, STERNFELD M, ELDOR A, GLICK D, SOREQ H: Structural roles of acetylcholinesterase variants in biology and pathology. Eut: Biochem. (1999) 264:672–686.
   PubMedGoogle Scholar
• •A thorough review of the non-catalytic roles of AChE.
   Google Scholar
• JOHNSON G, MOORE SW: The adhesion function on acetylcholinesterase is located at the peripheral anionic site. Biochem. Biophys. Res. Commun. (1999) 258:758–762.
   PubMed Web of Science ®Google Scholar
• DE FERRARI GV, CANALES MA, SHIN I, WEINER LM, SILMAN I, INESTROSA NC: A structural motif of acetylcholinesterase that promotes amyloid 3-peptide fibril formation. Biochemistry (2001) 40:10447–10457.
   PubMed Web of Science ®Google Scholar
• YU Q, HOLLOWAY HW, UTSUKI T, BROSSI A, GREIG NH: Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J. Med. Chem. (1999) 42:1855–1861.
   PubMed Web of Science ®Google Scholar
• YU Q, HOLLOWAY HW, FLIPPEN-ANDERSON JL, HOFFMAN B, BROSSI A, GREIG NH: Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. Med. Chem. (2001) 44:4062–4071.
   Google Scholar
• GIACOBINI E, SPIEGEL R, ENZ A, VEROFF AE, CUTLER NR: Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. j. Neural. Tansm. (2002) 109:1053–1065.
   PubMed Web of Science ®Google Scholar
• •In this paper, the first evidence of a correlation between central BuChE inhibition and cognitive improvement in AD patients is reported.
   Google Scholar
• BRUFANI M, CASTELLANO C, MARTA M et al: A long-lasting cholinesterase inhibitor affecting neural and behavioral processes. Pharmacol Biochem. Behav. (1987) 26:625–629.
   PubMedGoogle Scholar
• MIDDLETON E Jr, KANDASWAMI C, THEOHARIDES TC: The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev (2000) 52:673–751.
   PubMedGoogle Scholar
• KRYGER G, SILMAN I, SUSSMAN JL: Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. I Physic] Paris (1998) 92:191–194.
   PubMed Web of Science ®Google Scholar
• ELLMAN GL, COURTNEY KD, ANDRES V, FEATHERSTONE PM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol (1961) 7:88–95.
   PubMed Web of Science ®Google Scholar
• DORAISWAMY PM, STEFFENS DC: Combination therapy for early Alzheimer's disease: what are we waiting for? Am. Geriatr. Soc. (1998) 46:1322–1324.
   PubMedGoogle Scholar
• BUTTERFIELD DA, DRAKE J, POCERNICH C, CASTEGNA A: Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid P-peptide. Trends MM. Med. (2001) 7:548–554.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, SCHULZER M, MCGEER EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology (1996) 47:425–432.
   PubMed Web of Science ®Google Scholar
• MCGEER PL: Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging (2000) 17:1–11.
   PubMedGoogle Scholar
• ENDOH M, KUNISHITA T, TABIRA T: No effect of anti-leprosy drugs in the prevention of Alzheimer's disease and 13-amyloid neurotoxicity. Neurol. Sci. (1999) 165:28–30.
   Google Scholar
• WISE PM: Estrogens and neuroprotection. Trends Endocrinol. Metab. (2002) 13:229–230.
   PubMed Web of Science ®Google Scholar
• EIKELENBOOM P, ZHAN SS, VAN GOOL WA, ALLSOP D: Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci. (1994) 15:447–450.
   PubMedGoogle Scholar
• SCHUBERT P, RUDOLPHI K: Interfering with the pathologic activation of microglial cells and astrocytes in dementia. Alzheimer Dis. Assoc. Disord (1998) 12 (Supp1.2):S21–28.
   Google Scholar
• FERRONI S, MARCHINI C, OGATA T, SCHUBERT P: Recovery of deficient cholinergic calcium signaling by adenosine in cultured rat cortical astrocytes. Neurosci. Res. (2002) 68:615–621.
   Google Scholar
• FOURNIER J, STEINBERG R, GAUTHIER T et al: Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience (1993) 55:629–641.
   PubMed Web of Science ®Google Scholar
• PAULSEN 0, MOSER El: A model of hippocampal memory encoding and retrieval: GABAergic control of synaptic plasticity. Trends Neurosci (1998) 21:273–278.
   PubMed Web of Science ®Google Scholar
• COLLINSON N, KUENZI FM, JAROLIMEK W et al.: Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the a5 subunit of the GABAA receptor. Neurosci. (2002) 22:5572–5580.
   PubMed Web of Science ®Google Scholar
• MELCHIORRE C, ANDRISANO V, BOLOGNESI ML et al.: Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. Med. Chem. (1998) 41:4186–4189.
   Google Scholar